Rezatomidine

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameRezatomidine
Drug Alias Name瑞扎咪定rezatomidinarezatomidinumAGN-203818AGN-XX/YY
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlpha-2a adrenergic receptor agonists
TargetsAlpha-2a adrenergic receptor
Therapy Area/IndicationsCystitis, InterstitialDiabetic NeuropathiesIrritable Bowel Syndrome +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerlandUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAllergan Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAllergan Plc
Active IndicationsN/A
Inactive IndicationsCystitis, InterstitialDiabetic NeuropathiesIrritable Bowel Syndrome +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG